While the Warburg effect and glutaminolysis have long been recognized as key metabolic adaptations,[38] lipid metabolism has emerged as a crucial driver of tumor progression.[39, 40, 41] Lipid metabolism reprogramming in hepatocellular carcinoma is often characterized by the upregulation of key lipogenic genes such as ACLY, ACC, FASN, and SCD, regulated by the SREBF1 pathway.[42, 43] This shift enhances the synthesis of fatty acids and cholesterol, which are indispensable for tumor growth, survival, and metastasis. The gene discussed is FASN; the disease is neoplasm.